Investigational drug · Phase 3
HLX11
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 10, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
13
Any phase or sponsor naming "HLX11"
First trial start
2022
Apr 25, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HLX11", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Cancer
- Breast Neoplasms
- HER2-positive Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HLX11" as an intervention, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
- A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerPivotal-lookingActive, not recruiting
Shanghai Henlius BiotechIndustry
NCT05346224 · 900 participants (planned) · Start Apr 25, 2022 · Primary completion May 15, 2024
Drug: HLX11; EU-Perjeta® · For: Breast Cancer; Breast Neoplasms; HER2-positive Breast Cancer
Sites: Bengbu, China; Hefei, China; Lu'an, China · 79 sites in all
- Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT07578116 · 562 participants (planned) · Start Mar 9, 2027 · Primary completion May 31, 2032
Drug: Cyclin-Dependent Kinase 4 Inhibitor; Cyclin-Dependent Kinase 6 Inhibitor and 7 more · For: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma; Oligometastatic Breast Carcinoma
Sites: Jonesboro, Arkansas; Derby, Connecticut; Fairfield, Connecticut · 59 sites in all
- Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02003209 · 315 participants · Start Feb 18, 2014 · Primary completion Oct 31, 2016
Drug: Aromatase Inhibition Therapy; Carboplatin and 4 more · For: HER2-Positive Breast Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Stage IB Breast Cancer AJCC v7 and 5 more
Sites: Fairbanks, Alaska; Hot Springs, Arkansas; Anaheim, California · 732 sites in all
- Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast CancerPivotal-lookingTerminated
National Cancer Institute (NCI)NIH
NCT03199885 · 190 participants · Start Apr 5, 2019 · Primary completion Apr 30, 2024
Drug: Atezolizumab; Docetaxel and 3 more · For: Metastatic Breast Adenocarcinoma; Metastatic HER2-Positive Breast Carcinoma; Recurrent Breast Adenocarcinoma and 5 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Gilbert, Arizona · 673 sites in all
- Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male SubjectsPivotal-lookingCompleted
Shanghai Henlius BiotechIndustry
NCT04411550 · 160 participants · Start Jul 1, 2020 · Primary completion Jul 1, 2021
Drug: HLX11; CN-Perjeta(Pertuzumab) and 2 more · For: Healthy Male Volunteers
Sites: Hefei, China
- Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialRecruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07407920 · 120 participants (planned) · Start Oct 9, 2025 · Primary completion Sep 30, 2028
Drug: Hormone Therapy; Pembrolizumab and 2 more · For: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Early Stage HER2-Positive Breast Carcinoma and 1 more
Sites: Houston, Texas
- Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11Not yet recruiting
Shanghai Henlius BiotechIndustry
NCT07776132 · 60 participants (planned) · Start Nov 15, 2026 · Primary completion Jan 31, 2027
Drug: HLX29; HLX11 · For: Health Adult Subjects
Sites: Melbourne, Australia
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT06136897 · 35 participants · Start Mar 23, 2017 · Primary completion Nov 3, 2021
Drug: Pertuzumab; Trastuzumab · For: Malignant Solid Neoplasm
Sites: Philadelphia, Pennsylvania
University of WashingtonAcademic, hospital or other
NCT04329065 · 25 participants (planned) · Start Apr 20, 2022 · Primary completion Dec 31, 2026
Drug: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine; Paclitaxel and 4 more · For: Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8
Sites: Seattle, Washington
Newest research
PubMed records naming it or its code names, newest first.
- HLX11: A Pertuzumab Biosimilar.
McGuigan A · BioDrugs 2026
- Neoadjuvant Pertuzumab Biosimilar HLX11 Versus Reference Pertuzumab for Early-stage or Locally Advanced Breast Cancer: A phase 3 Equivalence Trial.
Zhang J, Zhu J, Yang Y, et al. · Clin Cancer Res 2026
- Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer.
Wei R, Zhang W, Yang F, et al. · J Transl Med 2024
- HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
Yang J, Lin L, Long Q, et al. · BioDrugs 2022
- Characterization and elimination of artificial non-covalent light Chain dimers in reduced CE-SDS analysis of pertuzumab.
Zhang L, Fei M, Tian Y, et al. · J Pharm Biomed Anal 2020
Also in development for Breast Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.